Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633521 | 0.86 | MAOB (0.57) | MEN1KMT2AMAOBRAB9ANPC1 | |
| SCHEMBL5936645 | 0.86 | MEN1 (0.53) | MEN1KMT2APOLBMAOBRAB9A | |
| SCHEMBL4170449 | 0.85 | MEN1 (0.52) | MEN1KMT2APOLBMAOBRAB9A | |
| SCHEMBL3823883 | 0.84 | MAOB (0.62) | MAOBRAB9AALOX5L3MBTL1MAOA | |
| SCHEMBL8335885 | 0.84 | ALOX5 (0.61) | MEN1KMT2AMAOBRAB9ANPC1 | |
| SCHEMBL1894067 | 0.83 | MAOB (0.58) | MEN1KMT2AMAOBRAB9ANPC1 | |
| SCHEMBL3629799 | 0.82 | MAOB (0.56) | MEN1KMT2AMAOBRAB9ANPC1 | |
| SCHEMBL1870380 | 0.82 | MEN1 (0.59) | MEN1KMT2APOLBMAOBRAB9A | |
| SCHEMBL1439758 | 0.81 | PPARD (0.58) | MEN1KMT2AMAOBRAB9ANPC1 | |
| SCHEMBL15287235 | 0.81 | MAOB (0.54) | MEN1KMT2AMAOBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230142277-A1 | POLYMERIZABLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-3421462-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3421462-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2021-09-30 | — | — | US | disclosed |
| CN-107699252-B | Polymeric liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1544208-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | MEN1 4074/4885KMT2A 3881/4885POLB 1831/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | MEN1 3144/4885KMT2A 3749/4885POLB 2035/4885 |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | MEN1 3144/4885KMT2A 3749/4885POLB 2035/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | MEN1 3144/4885KMT2A 3749/4885POLB 2035/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | MEN1 3324/4885KMT2A 888/4885POLB 2492/4885 |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, SNCA | MEN1 4422/4885KMT2A 2102/4885POLB 2470/4885 |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, SNCA | MEN1 4422/4885KMT2A 2102/4885POLB 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.